Clinical Focus

Previous Articles     Next Articles

Oral hypoglycemic agents in  treatment of type 2 diabetes mellitus

  

  1. Key Laboratory of Endocrinology, Ministry of Health; Peking Union Medical College,
    Chinese Academy of Medical Sciences, Beijing 100730, China
  • Online:2016-09-05 Published:2016-08-31
  • Contact: Corresponding author: Xiao Xinhua, Email: xiaoxh2014@vip.163.com

Abstract: Type 2 diabetes mellitus (T2DM) is a chronic, progressive disease characterized by insulin resistance and impaired β cell function. The prevalence of T2DM is growing steadily. In recent years, advanced knowledge of the pathologic mechanisms of T2DM, such as decreased incretin effect, neurotransmitter dysfunction and abnormal renal handing of hyperglycemia lead to the development and use of novel treatments that target the mechanisms for T2DM. The review will describe the effectiveness and safety of some novel oral hypoglycemic agents.

Key words: diabetes mellitus, type 2;glucagonlike peptide 1;dipeptidylpeptidase Ⅳ inhibitors